Eatontown, NJ, January, 4 2017. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Acetazolamide Immediate-Release 125 and 250mg tablets. This launch adds to Avet’s robust portfolio of generic oral solid products. Acetazolamide is the AB rated generic equivalent to the carbonic anhydrase inhibitor drug Diamox®. It is indicated for the treatment of glaucoma, epilepsy, mountain sickness and fluid retention. According to IMS data for the twelve-months ended November 2016, the U.S. market for Acetazolamide IR tablets is approximately $61 million. o Please also use the above to add an announcement onto the scrolling ‘Latest News’ bar Feel free to call if you need any further clarification.